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ABSTRACT 
Vaccines for pathogenic Strains of bovine herpesvirus 1 
(BHV-1) which are based on attenuated BHV-1 having a 
mutation in the latency-related gene are provided. Live, 
attenuated vaccines are also provided which express anti 
gens from other viral or bacterial pathogens and thus form 
the basis of a variety of vaccines. 
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WACCNES CONTAINING BOVINE HERPESVIRUS 
1 ATTENUATED BY MUTATION IN 
LATENCY-RELATED GENE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
0001. This application is based on U.S. Provisional 
Application Serial No. 60/437,855, filed on Jan. 3, 2003 
which is hereby incorporated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
0002 This invention was made with government support 
under grants from the U.S. Department of Agriculture, 
numbers 9802064 and 2000-02060 and grant number 
P2ORR15635 from the National Institutes of Health. The 
government has certain rights in this invention. 
BACKGROUND OF THE INVENTION 
0003. The present invention relates generally to vaccines 
based on live, attenuated viruses and to methods of using 
these vaccines. More particularly, the present invention 
relates to vaccines based on bovine herpesvirus 1, attenuated 
by mutation in the latency-related gene, and to methods for 
using these vaccines to induce immunological response to 
BHV-1 Specific and/or recombinant immunogenic antigens 
without reactivation of the virus from latency. 
0004. The publications and other materials used herein to 
illuminate the background of the invention or provide addi 
tional details respecting the practice, are incorporated by 
reference, and for convenience are respectively grouped in 
the appended List of References. 
0005) Bovine herpesvirus 1 (BHV-1) is an important viral 
pathogen of cattle that can cause Severe respiratory infec 
tion, conjunctivitis, abortions, Vulvovaginitis, balanoposthi 
tis, and Systemic infection in neonate calves (Wyler et al., 
1989). BHV-1 infection is also an important component of 
the upper respiratory tract infection referred to as "shipping 
fever” or bovine respiratory complex (Tikoo et al., 1995). 
BHV-1 is not the sole infectious agent associated with 
Shipping fever, but it initiates the disorder by immuno 
Suppressing infected cattle, which results in Secondary bac 
terial infections and pneumonia. Increased Susceptibility to 
Secondary infection correlates with depressed cell-mediated 
immunity after BHV-1 infection (Carter et al., 1989; Griebel 
et al., 1990; Griebel et al., 1987A; Griebel et al., 1987B). 
CD8" T-cell recognition of infected cells is impaired by 
repressing expression of major histocompatibility complex 
class I and of the transporter associated with antigen pre 
sentation (Hariharan et al., 1993; Hinkley et al., 1998; 
Naturaj et al., 1997). CD4" T-cell function is impaired 
during acute infection of calves, in part, because BHV-1 
infects CD4 T cells and induces apoptosis (Winkler et al., 
1999). BHV-1 infection costs the cattle industry millions of 
dollars per year in the United States. Following acute 
infection, BHV-1 establishes lifelong latency in ganglionic 
neurons of the peripheral nervous System after initial repli 
cation in mucosal epithelium. Reactivation from latency 
results in Virus Shedding and transmission to other Suscep 
tible animals. Reactivation occurs after natural or corticOS 
teroid-induced stress (Rock et al., 1992; Sheffy and Davies, 
1972). Although modified live vaccines are available, there 
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are disadvantages associated with the use of currently avail 
able vaccines, for example, they can cause disease in young 
calves or abortions in cows, and all have the potential to 
establish latency and reactivate from latency (Jones et al., 
2000). 
0006. In order to overcome these disadvantages, 
improved live attenuated vaccines that are effective against 
BHV-1 and other viral and bacterial pathogens, and which 
will not reactivate from latency, are needed. 
BRIEF SUMMARY OF THE INVENTION 
0007. It is an object of the present invention to provide 
live viral vaccines based on BHV-1 attenuated by mutation 
in the latency-related (LR) gene so that the BHV-1 does not 
reactivate from latency. These live, attenuated Viral vaccines 
cause acute infection and produce Sufficient viral titer to 
elicit a cell-mediated immune response. 
0008. It is another object of the present invention to 
provide live viral vaccines based on BHV-1 attenuated by 
mutation in the LR gene which express recombinant immu 
nogenic antigens. These attenuated viral vaccines cause 
acute infection and produce a specific antibody response to 
the recombinant antigens. The recombinant antigens may be 
one or more BHV-1 antigens or antigens of other viral or 
bacterial pathogens, or both. 
0009. It is a further object of the present invention to 
provide methods for effecting prophylactic treatment of viral 
or bacterial infection through the use of the live, attenuated 
Viral vaccines of the present invention, wherein the vaccine 
is administered to an animal in need of treatment and 
induces immunological response to viral or bacterial patho 
genS. 
0010. According to the present invention, the foregoing 
and other objects are achieved by the discovery, as described 
in further detail herein, that the LR gene of BHV-1 is 
necessary for reactivation of the virus from latency, and that 
the LR mutant of BHV-1 is able to grow and cause acute 
intranasal infection, and is therefore able to elicit an immu 
nological response in an infected animal. The vaccines of the 
present invention utilize live BHV-1, attenuated by mutation 
of the LR gene, to express BHV-1 specific and/or recombi 
nant immunogenic antigens and, thus, induce immunologi 
cal response to viral and bacterial pathogens. The vaccines 
of the present invention may be administered using one or 
more routes, including, but not limited to, Subcutaneous, 
intramuscular, intranasal, intraperitoneal, and ocular. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0011 FIG. 1 shows isolation and titration of virus 
present in trigeminal ganglia (TG) during acute infection. 
Virus was isolated from TG of mock, LR mutant, or wild 
type (WT) infected calves on the designated days postin 
fection, as further described in Example 1. The titer of 
infectious virus was determined on bovine kidney cells 
(MDBK) as described in Example 1. The data shown are the 
averages from each group. A value of 0.2 was used to denote 
a negative result in order to visualize the bars. 
0012 FIG. 2 shows DNA sequences of the wild-type 
(wt) (SEQ ID NO:7) and LR mutant (SEQ ID NO:8). DNA 
was prepared from TG as described in Example 1. Primers 
P4 and P5 (Inman et al., 2001B) were used to amplify a 
US 2004/0185056A1 
region that contains the mutated Sequences, including a 
unique EcoRI site. The amplified products were then 
digested with EcoRI (position in LR mutant is underlined) 
and visualized by ethidium bromide Staining on 2% agarose 
gel electrophoresis. 
0013 FIG. 3 shows BHV-1 neutralizing antibody titers 
post infection and after DEX treatment, as indicated, mea 
Sured as described in Example 1. Solid rectangles represent 
calves infected with wt virus, Solid triangles represent 
LR-rescued virus, and open rectangles represent calves 
infected with the LR mutant virus. Each time point repre 
Sents at least four calves. The inset panel is shown to 
illustrate the differences during acute phase more clearly 
(the x-axis scale is altered). The differences between the 
time points after 10 days postreactivation were Statistically 
significant (P<0.05). 
0.014 FIG. 4 shows viral shedding from ocular and nasal 
cavities after dexamethasone-induced reactivation deter 
mined using the procedures of Example 1. Shown are the 
percentages of calves that shed BHV-1 virus/total number of 
calves in each group on the designated day after dexam 
ethasone (DEX) treatment. Four calves were used for the 
study with the LR-rescued virus, seven were used for the wt 
(WT) study, and seven were used for the study with the LR 
mutant. 
SUMMARY OF THE SEQUENCES 
0015 SEQID NO:1 is the nucleotide sequence for primer 
p4. 
0016 SEQID NO:2 is the nucleotide sequence for primer 
p5. 
0017 SEQ ID NO:3 is the nucleotide sequence for for 
ward primer gC. 
0018 SEQ ID NO:4 is the nucleotide sequence for 
reverse primer gC. 
0019 SEQ ID NO:5 is the nucleotide sequence for for 
ward primer gh. 
0020 SEQ ID NO:6 is the nucleotide sequence for 
reverse primer gh. 
0021 SEQ ID NO:7 is the nucleotide sequence of the 
wild-type BHV-1 latency-related ORF2 shown in FIG. 2. 
0022 SEQID NO:8 is the nucleotide sequence of the LR 
mutant oligonucleotide shown in FIG. 2. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENT 
0023 The present invention is directed to live, attenuated 
vaccines based on BHV-1 attenuated by mutation in the 
latency-related (LR) gene. The discovery, described in detail 
herein, that the LR gene of BHV-1 is not required to 
establish acute intranasal infection, and that the LR gene is 
essential for reactivation of BHV-1 from latency, makes 
possible the construction of live attenuated BHV-1 vaccines 
which are capable of inducing immune responses without 
reactivation from latency. 
0024. In one embodiment, the vaccines of the present 
invention provide immune System exposure to epitopes on 
the attenuated BHV-1 virus and induce immunological 
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response to pathogenic strains of BHV-1. In another embodi 
ment, the vaccines of the present invention provide immune 
System exposure to one or more recombinant antigens of 
BHV-1 and/or other pathogenic viruses or bacteria. The 
present invention can be practiced with a variety of Viral and 
bacterial pathogens, including, without limitation, those 
which colonize and grow in the upper respiratory tract or 
other mucosal Surfaces. Examples of Such pathogens include 
bovine viral diarrhea virus (BVDV), bovine respiratory 
virus (BRSV), bovine corona viruses, and bacterial strains 
commonly associated with “Shipping Fever” (Pasteurella 
haemolytica, Pasteurella multocida, and Haemophilus SOm 
nus for example). The vaccines of the present invention are 
useful with mammals, preferably ungulates, most preferably 
with sheep, bovines, deer, and buffalo. 
0025 The present invention is further directed to meth 
ods for effecting treatment of infections through adminis 
tration of the vaccines of the present invention to induce 
immunity in an animal in need of treatment. In one embodi 
ment, the treatment is of a BHV-1 infection. In another 
embodiment, the treatment is of infection with a different 
pathogenic virus or a pathogenic bacterium. 
0026 BHV-1 is a member of the Alphaherpesvirinae 
Subfamily and shares certain biological properties with 
herpes simplex virus types 1 and 2 (HSV-1 and -2, respec 
tively) (Jones 1998). Viral gene expression in BHV-1 is 
temporally regulated in three distinct phases: immediate 
early (IE), early (E), or late (L). Two IE transcription units 
exist: IE transcription unit 1 (IEtu1) and IEtu2. IEtu1 
encodes functional homologues of two HSV-1 IE proteins, 
ICP0 and ICP4. IEtu2 encodes a protein that is similar to an 
essential HSVIE protein, ICP22 (Wirth et al., 1991). Bovine 
ICP0 (bCPO) is very important for productive infection, 
because it activates all classes of viral promoters and is 
expressed at high levels throughout infection (Fraefel et al., 
1994; Wirth et al., 1992; Wirth et al., 1991). 
0027) Although the primary site of BHV-1 latency is 
Sensory neurons, there is evidence that long-term persistence 
and reactivation also occur within germinal centers of pha 
ryngeal tonsil (Winkler et al., 2000). The latency-related 
RNA (LR-RNA) is the only abundant viral transcript 
detected in latently infected neurons (Kutish et al., 1990; 
Rock et al., 1992; Rock et al., 1987A). A fraction of 
LR-RNA is polyadenylated and alternatively spliced in 
trigeminal ganglia (TG), Suggesting this RNA is translated 
into more than one LR protein (LRP) (Devireddy and Jones, 
1998; Hossain et al., 1995). LR gene products effect the 
normal cell cycle by inhibiting entry into S-phase. LRP is 
associated with cyclin-dependent kinase 2 (cdk2)-cyclin 
complexes (Hossain et al., 1995; Jiang et al., 1998). LR gene 
products also promote cell Survival following induction of 
apoptosis in transiently transfected cells (Ciacci-Zanella et 
al, 1999). 
0028. Similar to BHV-1, HSV-1 establishes latency in 
ganglionic Sensory neurons, typically TG or Sacral dorsal 
root ganglia (Jones 1998; Wagner and Bloom, 1997). In situ 
hybridization has revealed that a Small region, the latency 
associated transcript (LAT), within the terminal repeats is 
abundantly transcribed in latently infected neurons (Rocket 
al., 1987B; Stevens et al., 1987). Numerous mutants that do 
not express detectable levels of LAT have been constructed. 
Although Several Studies have Suggested that LAT plays no 
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role in a latent infection, for example (Blocket al., 1990; Ho 
and Mocarski, 1988), most have concluded that LAT is 
important, but not required. LAT enhances establishment of 
latency in mice (Sawtell, 1992; Thompson and Sawtell, 
1997) and rabbits (Perng et al., 2000B), because certain 
LAT-null mutants contain lower levels of viral DNA in TG 
relative to wt virus (Devi-Rao et al., 1994; Maggioncalda et 
al., 1996). LAT interferes with apoptosis in transiently 
transfected cells and in infected mice or rabbits (Ahmed et 
al., 2002; Inman et al., 2001A; Perng et al., 2000A). The 
ability of LAT to interfere with apoptosis correlates with its 
ability to promote spontaneous reactivation (Inman et al., 
2001A), Suggesting the antiapoptotic activity of LAT has 
biological significance with respect to latency. 
0029. Although the LR gene of BHV-1 is homologue of 
the HSV-1 LAT gene, there are several notable differences. 
Most notably, the evidence presented herein shows that LR 
mutant BHV-1 does not reactivate from latency. In contrast, 
LAT-null mutants have been reported to reactivate from 
latency. Furthermore, the primary LAT transcript is 6.3 kb 
and includes two genes (Zwaagstra et al., 1990), whereas the 
primary LR transcript is only 1.5 kb and one gene (Kutish 
et al., 1990), and there is no obvious sequence homology 
between LR-RNA and LAT. While the region of LAT to 
which the Spontaneous reactivation phenotype maps does 
not appear to encode a protein involved in the latency 
reactivation cycle (Dorlet et al., 1998), the BHV-1 LR gene 
does encode Such a protein (Jiang et al., 1998). Although an 
open reading frame in the stable 2-kb LAT may encode a 
protein (Coffin et al., 1998; Thomas et al., 1999), this protein 
is unlikely to play an important role in reactivation Since it 
is located outside the region of LAT to which the reactiva 
tion function maps in rabbits (Bloom et al., 1996; Perng et 
al., 2001) and mice. Expression of an LR protein appears to 
play a role in protecting cells from death (Ciacci-Zanella et 
al., 1999). Finally, the LR gene has also been shown to 
inhibit cell cycle progression (Schang et al., 1996) and in the 
context of the Viral genome plays an important role in Virus 
shedding in the eyes of infected calves (Inman et al., 2001). 
Thus, structurally, the LR and LAT genes and RNAS are very 
different. 
0030) Definitions. 
0031. The present invention employs the following defi 
nitions, which are, where appropriate, referenced to BHV-1. 
0032. An “antigen” refers to a molecule containing one or 
more epitopes that will Stimulate a host's immune System to 
make a Secretory, humoral and/or cellular antigen-Specific 
response. 
0033. The specific antigen can be a protein, a polysac 
charide, a lipopolysaccharide or a lipopeptide; or it can be a 
combination of any of these. Particularly, the Specific anti 
gen can include a native protein or protein fragment, or a 
Synthetic protein or protein fragment or peptide; it can 
include glycoprotein, glycopeptide, lipoprotein, lipopeptide, 
nucleoprotein, nucleopeptide; it can include a peptide-pep 
tide conjugate; or it can include a recombinant nucleic acid 
expression product. Examples of antigens include, without 
limitation, those that are capable of eliciting an immune 
response against Viral or bacterial bovine herpes virus, 
bovine respiratory virus, bovine viral diarrhea virus, bovine 
corona virus, and bacterial Strains commonly associated 
with “shipping fever”. 
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0034. The term “effective amount of an antigen” may be 
an amount capable of eliciting a demonstrable humoral, 
Secretory, and/or cell-mediated immune response. The 
appropriate amount of antigen to be used is dependent on the 
Specific antigen and is well known in the art. 
0035 “Encode.” A polynucleotide is said to “encode” a 
polypeptide if, in its native State or when manipulated by 
methods well known to those skilled in the art, it can be 
transcribed and/or translated to produce the mRNA for the 
polypeptide and/or a fragment thereof. The anti-Sense Strand 
is the complement of Such a nucleic acid, and the encoding 
Sequence can be deduced therefrom. 
0036) “Immunization” refers to the process of inducing a 
continuing protective level of antibody and/or cellular 
immune response which is directed against an antigen to 
which the organism has been previously exposed. 
0037. An “immunological response' to a vaccine is the 
development in the host of a humoral, Secretory, and/or 
cell-mediated immune response to the vaccine of interest. 
An immunological response is usually assayed with an 
immunoassay. A variety of immunoassay methods are well 
known in the art. See, e.g., Harlow and Lane, 1988, or 
Goding, 1986. 
0038 “Latency-reactivation cycle” refers to a process 
operationally divided into three major Steps: establishment 
of latency, maintenance of latency, and reactivation. Estab 
lishment of latency includes entry of the viral genome into 
a Sensory neuron and acute infection. In BHV-1, Viral gene 
expression is then generally extinguished, with the excep 
tion of the latency-related transcript (LR). Maintenance of 
latency is a phase that lasts for the life of the host and can 
be operationally defined as a period when infectious virus is 
not detected by Standard virus isolation procedures. In 
general, abundant expression of Viral genes that are required 
for productive infection does not occur during maintenance 
of latency. LR is the only known viral transcript that is 
abundantly expressed during this stage of latency. “Reacti 
vation” and “reactivation from latency” refer to the process 
of Viral reactivation which and Stimulation of viral gene 
expression which occurs after exogenous administration of 
corticosteroids or elevated levels of natural corticosteroids 
as a consequence of StreSS. The Synthetic corticosteroid 
dexamethasone (DEX) efficiently reactivates BHV-1 in 
latently infected rabbits and calves (Rocket al., 1992; Sheffy 
and Davies, 1972). Immunosuppression may also stimulate 
Viral gene expression to cause reactivation. Upon reactiva 
tion, abundant Viral gene expression may be detected in 
sensory neurons, and infectious BHV-1 virus can be isolated 
from TG, eye Swabs, and/or nasal Swabs. During reactiva 
tion, Virus is translocated back to the initial Site of infection, 
from which it can spread to other susceptible hosts. The 
ability to reactivate from latency results in recurrent disease 
and virus transmission. 
0039 “Operably linked” refers to a juxtaposition of com 
ponents wherein the components So described are in a 
relationship permitting them to function in their intended 
manner. For instance, a promoter is operably linked to a 
coding Sequence if the promoter affects its transcription or 
expression. 
0040) “Recombinant nucleic acid” is a nucleic acid which 
is not naturally occurring, or which is made by the artificial 
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combination of two otherwise Separated Segments of 
Sequence. This artificial combination is often accomplished 
by either chemical Synthesis means, or by the artificial 
manipulation of isolated Segments of nucleic acids, e.g., by 
genetic engineering techniques. Such is usually done to 
replace a codon with a redundant codon encoding the same 
or a conservative amino acid, while typically introducing or 
removing a Sequence recognition site. Alternatively, it is 
performed to join together nucleic acid Segments of desired 
functions to generate a desired combination of functions. A 
polypeptide produced as an expression product of an iso 
lated and manipulated genetic Sequence is an "isolated 
polypeptide', as used herein, even if expressed in a homolo 
gous cell type. Synthetically made forms or molecules 
expressing by heterologous cells are inherently isolated 
molecules. 
0041 A“recombinant vector' of the present invention is 
a live BHV-1 virus attenuated by mutation in the latency 
related gene and expresses recombinant immunogenic anti 
gens of one or more pathogen. 
0.042 “Treatment” refers to the administration to an indi 
vidual of a composition which yields a immunological 
response, and includes prophylaxis and/or therapy. 
0.043 “Vaccine composition” and “vaccine” refer to an 
agent used to Stimulate the immune System of an individual 
So that current harm is alleviated, or protection against future 
harm is provided. 
0044 As described in further detail herein (Example 4), 
and in Perng et al. (2002), incorporated herein in its entirety 
by reference, the LR gene was inserted into the LAT locus 
to determine whether it could restore Spontaneous reactiva 
tion to a LAT-null mutant. It has been discovered that the LR 
gene of BHV-1 is capable of restoring high levels of 
Spontaneous reactivation from latency to a LAT-null mutant, 
adding Support to the hypothesis that inhibition of apoptosis 
plays an important role in the latency reactivation cycle of 
HSV-1 and BHV-1. 
0.045 An LR mutant was constructed by inserting three 
Stop codons near the beginning of the LR-RNA, Suggesting 
that expression of LR proteins would be altered. The LR 
mutant grew with wild-type (wt) efficiency in bovine kidney 
cells (MDBK). Calves infected with the LR mutant consis 
tently exhibited diminished clinical Symptoms and a dra 
matic decrease (3 to 4 logs) in ocular, but not nasal, viral 
Shedding occurred during acute infection compared to the wt 
or the LR-rescued virus (Inman et al., 2001). Conversely, the 
LR mutant had similar growth properties in productively 
infected bovine kidney cells (MDBK) and the nasal cavity of 
calves during acute infection. These results Suggested that 
LR gene products promote virus growth in certain cell types 
in the eye or optic nerve during acute infection of cattle. 
0046) The evidence presented herein compares the 
latency reactivation cycle in calves infected with the LR 
mutant and to those from calves infected with wt BHV-1 or 
the LR-rescued virus. This application reports the results of 
examining the effects of the LR mutant on Virus production 
in TG and the latency reactivation cycle. Diminished levels 
of virus were detected in TG of calves acutely infected with 
the LR mutant when compared to those infected with wt or 
LR-rescued virus. Although we consistently detected LR 
RNA in TG of calves infected with the LR mutant or the wt 
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by PCR, we were unable to detect viral DNA in neurons of 
calves infected with the LR mutant by in situ hybridization. 
PCR analysis confirmed that calves infected with the LR 
mutant contained lower levels of viral DNA during latency 
compared to those in calves infected with wt BHV-1. The 
evidence reported herein further shows that the LR mutant 
Virus was not reactivated from latently infected calves 
following treatment with dexamethasone (DEX). In con 
trast, calves infected with wt virus or the LR-rescued virus 
reactivated efficiently following the same DEX treatment. 
The results described herein demonstrate that wt expression 
of LR gene products plays a crucial role in the latency 
reactivation cycle of BHV-1 in cattle. 
0047 As described herein in further detail, the LR mutant 
did not reactivate from DEX-induced reactivation, whereas 
the wt or LR-rescued virus did. The LR mutant contains 
three stop codons near the beginning of the LR-RNA that are 
designed to prohibit protein expression from all three read 
ing frames (Inman et al., 2001B). The LR mutant also lacks 
25 bp from Wt Sequence to prevent reversion to the wt. A 
peptide antibody that is directed against amino acid 
Sequences within the LR open reading frame (ORF2) rec 
ognizes a protein of approximately 40 kDa in cells trans 
fected with a wt LR gene construct (Ciacci-Zanella et al., 
1999; Hossain et al., 1995; Jiang et al., 1998), but not when 
transfected with a plasmid containing the mutation used to 
make the LR mutant virus (Ciacci-Zanella et al., 1999). 
While not wanting to be bound by any particular theory, it 
appears that any phenotypic difference between the LR 
mutant and wt or LR-rescued virus is attributable to lack of 
protein expression by the LR mutant. Because the LR-RNA 
is alternatively spliced (Devireddy and Jones, 1998), there is 
the possibility that more than one protein is expressed. 
However, it is possible that differences in LR-RNA expres 
sion between wt BHV-1 and the LR mutant were responsible 
for the attenuated phenotype. Regardless of whether an LR 
protein or changes in LR-RNA mediate the altered pheno 
type of the LR mutant, the results reported herein clearly 
demonstrated that the latency reactivation cycle was dis 
rupted following infection of calves with the LR mutant. 
0048. The TG is divided into three sections (ophthalmic, 
maxillary, and mandibular), and each Section innervates the 
eye, nose, or mouth, respectively. Following infection of 
calves with the LR mutant, a 3- to 4-log reduction in Virus 
Shedding from ocular Swabs was detected compared to the 
level in calves infected with wt or LR-rescued virus (Inman 
et al., 2001B). In contrast, shedding of the LR mutant from 
the nasal cavity during acute infection was not significantly 
different from that of wt BHV-1 or the LR-rescued virus. 
Without being bound to a particular mode of action, the 
results reported herein Suggest that “Seeding of the TG by 
the LR mutant would be fairly normal via the maxillary 
route following infection, but lower levels of virus would 
seed the TG via the ocular route. Considering that it was not 
possible to reactivate the LR mutant and lower levels of viral 
DNA were detected in TG of calves latently infected with 
the LR mutant, it may be that seeding of viral DNA via the 
ocular route is more important. It is also possible that 
regardless of whether the LR mutant seeds the TG via the 
maxillary or ocular route, efficient amplification of the viral 
genome or reactivation from latency would not occur. The 
finding that 10- to 100-fold less infectious virus was present 
in TG of calves acutely infected with the LR mutant supports 
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the contention that wt expression of LR gene products was 
important for acute infection of Sensory neurons. 
0049. Several reports have demonstrated that HSV-1 LAT 
plays an important role in establishing (versus reactivation) 
latency (Perng et al., 2000B; Sawtell, 1997; Sawtell, 1992), 
Suggesting LR gene products also play a role in establishing 
latency. Two findings in this Study Support a role for wt 
expression of LR gene products in the establishment of 
latency. First, reduced levels of viral DNA were detected in 
calves latently infected with the LR mutant. Second, the 
failure to detect in Situ hybridization-positive neurons in 
calves latently infected with the LR mutant Suggested that 
LR gene products were necessary for latency in neurons 
containing high copies of viral DNA. While not wanting to 
be bound by a particular mode of action, it is possible that 
LR gene products promote (i) productive infection in certain 
neurons, (ii) Survival of "permissive' neurons that Support 
productive infection, or (iii) infection of certain types of 
neurons. Considering that LR gene products interfere with 
apoptosis in transiently transfected cells (Ciacci-Zanella et 
al, 1999) and HSV-1 LAT interferes with apoptosis (Ahmed 
et al., 2002, Inman et al., 2001A; Perng et al., 2000A), it is 
tempting to speculate that LR gene products promote neu 
ronal Survival in TG of infected calves during acute infec 
tion. 
0050 Infectious virus was not detected in calves latently 
infected with the LR mutant following DEX treatment to 
initiate reactivation (FIGS. 3 and 4). No changes in virus 
Specific antibodies were detected during the course of reac 
tivation. An increase in Virus-specific antibodies is a Sensi 
tive method to detect reactivation from BHV-1 (Jones et al., 
2000) and HSV-1 (Perng et al., 1999). Furthermore, multiple 
injections of DEX were used to ensure that reactivation 
occurred. By using a similar protocol, a modified live 
vaccine strain of BHV-1 that is severely attenuated has been 
reactivated (Jones et al., 2000). It is generally accepted that 
the amount of viral DNA in TG of HSV-1-infected Small 
animal models plays a role in the efficiency of reactivation 
(Jones 1998; Wagner and Bloom, 1997), implying there is a 
similar mechanism for BHV-1. As discussed above, calves 
infected with the wt, but not the LR mutant, have neurons 
with high levels of viral DNA and reactivate efficiently. 
0051). In general, HSV-1 LAT has been shown to be 
important, but not required, for latency reactivation in 
rabbits and mouse models (Jones 1998; Wagner and Bloom, 
1997). The results reported herein show that wt expression 
of LR gene products was required for the latency reactiva 
tion cycle in calves when reactivation was initiated by DEX. 
One possible explanation for this is that the LR gene is more 
important than LAT for the latency reactivation. BHV-1 
lackS. Several genes contained in the HSV-1 genome, which 
mediate pathogenesis and/or latency: the 34.5 gene, for 
example (Schwyzer and Ackermann, 1996). The 34.5 gene 
plays a crucial role in neurovirulence by inhibiting antiviral 
functions of the interferon-inducible double-stranded RNA 
dependent protein kinase R (Chou et al., 1995; Leib et al., 
2000). 34.5-null mutants have reduced pathogenesis in rab 
bits and mice, in large part because of poor growth proper 
ties in the eyes and TG (Perng et al., 1995). Since LR gene 
products play a role in ocular growth of BHV-1 in calves 
(Inman et al., 2001B) and lower levels of infectious virus 
were detected in TG of calves acutely infected with the LR 
mutant (FIG. 1), they have additional properties that have 
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not been described for HSV-1 LAT. The LR gene restores 
Spontaneous reactivation to a McKrae LAT-null mutant 
(dLAT2903), demonstrating that LAT and LR gene products 
have common functional properties that are necessary for 
efficient reactivation from latency (Perng et al., 2002). In 
addition, the LR gene enhanced the ability of dLAT2903 to 
kill mice during acute infection and induce recurrent eye 
disease in latently infected rabbits, underScoring our hypoth 
esis that LR gene products have expanded roles during the 
latency reactivation cycle and even pathogenesis when com 
pared to LAT. 
0.052 Method of Use: Vaccines for Bovine Herpesvirus 1 
0053 Novel BHV-1 vaccines of the present invention are 
based on the discovery that: 1) the LR gene of BHV-1 is not 
required to establish acute intranasal infection; and 2) the 
LR gene is essential for reactivation of BHV-1 from latency. 
The present invention accordingly seeks to provide novel 
vaccines based on live BHV-1, attenuated by mutation in the 
latency-related gene, which elicit an immune response in the 
host, however do not reactivate from latency. 
0054 BHV-1 strains comprising a mutation in the LR 
gene are provided. The mutation can be obtained by means 
well known in the art, Such as but not limited to, genetic 
engineering techniques, chemical Synthesis, mutant Selec 
tion techniques, or the method described in Example 2. Any 
methods which do not interrupt blCP0 gene expression, yet 
interrupt LR gene expression, may be employed. 
0055. In a preferred method, the mutant oligonucleotide 
is inserted into the Cooper strain of BHV-1 (ATCC No. 
VR-864). In addition to the LR mutation, one or more 
additional deletions or modifications to the coding 
Sequences of a glycoprotein are preferably included to 
further attenuate the Cooper Strain of BHV-1. Examples of 
BHV-1 glycoprotein genes that can be deleted, or modified 
by insertion, Substitution or otherwise are: glycoprotein C, 
glycoprotein D, glycoprotein E, glycoprotein G, glycopro 
tein H, or glycoprotein I. Although this is a preferred 
embodiment, other means to arrive at an LR-null mutant 
may be used in the practice of the invention. Further, a 
mutant LR gene could be inserted into other commercially 
available strains of BHV-1, for example, without limitation, 
BovaShield (Pfizer, Inc.) or the temperature sensitive mutant 
described in Jones et al. (2000). In one preferred embodi 
ment, the BHV-1 strain is less virulent than the Cooper strain 
of BHV-1. Further mutations may be made using the plas 
mid (pBlueL/mLAT) (Inman et al., 2001B). Briefly, plasmid 
(pBlueL/mLAT) can be constructed as follows: 825 base 
pairs (bp) of the BHV-1 HindIII L fragment that is directly 
upstream of the LR promoter (D fragment) are cloned into 
pBlueBachis.A (InVitrogen, Carlsbad, Calif.), pBR322-Hin 
dIII L-fragment contains the HindIII L fragment of BHV-1 
(Cooper Strain) and this plasmid is digested with NheI. The 
resulting products are treated with Mung Bean exonuclease 
(New England BioLabs) to blunt the ends for ligation of 
BamHI linkers. After phenol and chloroform extraction, the 
DNA is digested with HindIII and then BamHI. The prod 
ucts are electrophoresed on an agarose gel and the 825 bp 
product isolated. The 825bp product containing a 5' BamHI 
site and a 3' Hind III site is ligated into the pBlueBachis 
vector digested with BamHI plus HindIII (resulting plasmid 
designated herein as pBlueL). A fragment containing the 
entire LR promoter and coding region (1940 bp) is cloned 
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into the HindIII and Sall sites of pBlueL (resulting plasmid 
designated herein as pBlueL/LAT). The PstI fragment 
(1-981 nt) is excised from pBlueL/LAT and cloned into 
pBlueBachis vector. This sub-cloning is performed because 
there are 3 SphI sites in the coding region of the LR gene 
(781, 812 and 1777 nt). The SphI fragment (781-812 NT) is 
excised and the mutant oligonucleotide inserted. The 
mutated Pst fragment is then cloned back into the original 
PstI digested pBlueL/LAT and the resulting construct (des 
ignated herein as pBlueL/mLAT). Restriction enzyme map 
ping and DNA sequencing can be used to determine proper 
orientation of the Pst fragment. All cloning procedures 
(restriction digests, ligations, CIP treatment, etc.) are per 
formed by standard procedures. All BHV-1 fragments can be 
obtained from the Cooper strain of BHV-1 (ATCC VR-864). 
0056. The coding sequences for the glycoprotein genes 
listed above are known, and primers can be designed to 
amplify these genes. Deletions can be generated using 
Standard molecular biology techniqueS Such as restriction 
enzyme digestions, PCR mediated mutagenesis, or site 
directed mutagenesis. These deletions are introduced back 
into the Cooper Strain using homologous recombination, as 
described in Example 2 for constructing the LR mutant. 
0057 Bovine epidermal cells are cotransfected with 6 ug 
pBlueL/mLAT, 2 ug of a plasmid encoding HSV-1 ICP0, and 
2 ug of Viral DNA using Superfect (Qiagen) as previously 
described (Inman et al., 2001B, Inman et al., 2002). Sixteen 
hours after transfection, cells are split 1:2, incubated for 16 
additional hours, and then overlaid with 0.7% Seaplaque 
agarose. When visible plaques appear (3-4 days after infec 
tion); each plaque is isolated, propagated in MDBK cells, 
and screened by PCR for the mutant oligonucleotide insert. 
PCR is performed on the extracted DNA using primer 4 (p4) 
(nt 873 5'CGTGTATTTGCGACCCCCAGCCT3) and 
primer 5 (p5) (nt 596 5'GCCAGACCAAAC 
CCCCCGCA3). After a hot start, each cycle consists of 95 
C. for 1 min., 60° C. for 1 min. and 72° C. for 2 min. (30 
cycles total). To ensure complete elongation of amplified 
products, the reaction is incubated at 72 C. for an additional 
10 minutes. Products are digested with EcoRI, electrophore 
Sed on a 2% agarose gel, and the DNA visualized by Staining 
with ethidium bromide. 
0.058 Isolation of intact BHV-1 viral DNA of the live 
attenuated vaccine Strain can be performed as previously 
described (Inman et al., 2001B, Inman et al., 2002). Briefly, 
MDBK cells can be infected with the BHV-1 Strain obtained 
from Pfizer at a multiplicity of infection of approximately 
10. The clarified lysate can be pelleted using a 30% sucrose/ 
TE cushion (25,000 rpm. for 2 h in a Beckman Lt.-65 using 
an SW28 rotor at 4° C). Virions can be disrupted with SDS, 
RNAse treatment, followed by proteinase K, and extraction 
with phenol/chloroform/isoamyl alcohol (50:48:2). The 
integrity and quantity of viral DNA is determined by 1% 
agarose gel electrophoresis. Stocks of virus can be prepared 
in MDBK cells as described previously (Inman et al., 
2001 B; Inman et al., 2002; Jones et al., 2000). 
0059 Vaccination of animals with the live attenuated 
vaccines of the present invention can be conducted by means 
well known in the art (Jones et al., 2000). Briefly, for 
intranasal instillation, calves can be inoculated with approxi 
mately 6.5 logo TCIDs/ml of the respective modified live 
vaccine strains. For IM vaccination, the modified live vac 
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cine can be injected into the flank (caudal muscle mass) or 
the neck (brachiocephalicus muscle) using 6.5 logo 
TCIDso/ml of the virus. An 18 gauge needle (1.5 inch) can 
be used for all IM injections, and the injection can contain 
approximately 0.5 ml. Because the attenuated virus can 
grow efficiently in the nasal cavity a robust BHV-1 specific 
antibody response occurs in infected calves. However, the 
clinical Symptoms and disease are not significant. The 
construction of a LR mutant and route of vaccination 
provided above are exemplary only, and any Suitable means 
known in the art may be used in the practice of the present 
invention 
0060 Method of Use: Vaccines for Non-Herpes Viral and 
Bacterial Pathogens 
0061 Novel vaccines based on live BHV-1 attenuated by 
mutation in the latency-related gene Such that the virus will 
not reactivate from latency, may be used to provide vaccines 
for a variety of viral and bacterial pathogens. Recombinant 
nucleic acids may be inserted into any region of the viral 
genome of attenuated BHV-1 strains of the present invention 
which is non-essential for infection of the host, using 
methods known in the art. For example, without limitation, 
two Such approaches are: 1) insertion of recombinant nucleic 
acid form the pathogen in the mutated LR gene locus Such 
that expression is driven by the LR promoter to which it is 
operably linked; and 2) insertion of recombinant nucleic 
acid from the pathogen gene into a glycoprotein locus of an 
LR mutant virus, and the expression of the pathogen nucleic 
acid driven by a foreign promoter to which it is operably 
linked. 
0062 For the first approach, the pBlueL/mLAT plasmid 
(Inman et al., 2001B) is modified to contain a unique PacI 
restriction enzyme site at nucleotide 781 of LR sequences 
(the first SphI site that was used to insert the mutant oligo). 
Genes from these pathogens are cloned and PacI sites added 
to the termini of these fragments. This approach permits 
expression of the foreign gene operably linked to the LR 
promoter in the context of the BHV-1 genome. 
0063 For the second approach, recombinant nucleic acid 
of other pathogens (or homologous nucleic acid of other 
BHV-1 antigens) are inserted into the glycoprotein C (gC) or 
glycoprotein E (gE) locus in the context of the LR mutant 
Virus. The gC and gF loci are chosen because these genes are 
not important for growth of the virus in cultured cells, thus 
readily permitting construction of recombinant viruses. The 
human cytomegalovirus promoter can be used to drive 
expression of the respective genes from other pathogens as 
this promoter is expressed efficiently during herpes simplex 
virus type 1 (HSV-1) acute infection, and thus can be 
expected to be expressed efficiently during BHV-1 produc 
tive infection. 
0064 Pathogens that are candidates for this approach 
include, without limitation: bovine viral diarrhea virus 
(BVDV), bovine respiratory virus (BRSV), bovine corona 
Viruses, and bacterial Strains commonly associated with 
“Shipping Fever” (Pasteurella haemolytica, Pasteurella 
multocida, and Haemophilus Somnus for example). For the 
Viruses listed, Structural proteins are used for foreign expres 
Sion. For the bacterial pathogens, immunogenic Surface 
proteins are used. 
0065. Following vaccination of calves, a specific immune 
response is induced against BHV-1 and the gene from the 
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respective foreign pathogen. This immune response is deter 
mined by measuring antibody responses. 
EXAMPLES 
0.066 The present invention is further described in the 
following examples, which are offered by way of illustration 
and are not intended to limit the invention in any manner. 
Standard techniques well known in the art or the techniques 
specifically described below are utilized. 
EXAMPLE 1. 
Materials and Methods 
0067 A. Virus and Cells 
0068 Bovine kidney cells (MDBK; ATCCCCL-22) were 
plated at a density of 5x10 per 100-mm plastic dish in 
Earle's modified medium supplemented with 5% fetal 
bovine serum (FBS), penicillin (10 U/ml), and streptomycin (100 lug/ml). 
0069. The Cooper strain of BHV-1 (wt virus) (ATCC 
VR-864) was obtained from the National Veterinary Ser 
vices Laboratory, Animal and Plant Health Inspection Ser 
vices, Ames, Iowa. A complete description of the LR mutant 
virus has been previously described (Inman et al., 2001B 
incorporated in full herein, by reference). Briefly, the LR 
mutant virus was developed by replacing wt (Cooper Strain) 
LR gene Sequences with an oligonucleotide that contains a 
unique EcoRI restriction Site and three Stop codons in each 
reading frame (FIG. 2). In transiently transfected cells, a 
plasmid with this mutation does not express detectable 
levels of the LR protein, but does express LR-RNA (Ciacci 
Zanella et al., 1999). Viral stocks were prepared by infecting 
MDBK cells with a multiplicity of infection (MOI) of 0.001 
from a plaque-purified virus. Virus was titrated on MDBK 
cells by using 10-fold dilutions and determining the 50% 
tissue culture infectious dose (TCIDs) or PFU. 
0070 B. Animal Experiments. 
0071 BHV-1-free crossbred calves (-250 kg) were ran 
domly assigned and housed in isolation rooms to prevent 
croSS contamination. Calves were anesthetized with Rom 
pun (approximately 1 mg/kg of body weight; Bayer Corp., 
Shawnee Mission, Kans). Calves were then inoculated with 
1 ml of a solution containing 107 PFU of the indicated virus 
per ml in each nostril and eye, without Scarification, for a 
total of 4x107 PFU per animal as described previously 
(Schang and Jones, 1997; Winkler et al., 1999; Winkler et 
al., 2000). Experiments with animals were performed in 
accordance with the American ASSociation of Laboratory 
Animal Care guidelines. At 60 days postinfection (dpi) 
(latency), calves were injected intravenously with 100 mg of 
DEX as described previously (Winkler et al., 2000). Addi 
tional intramuscular injections (25 mg) of DEX were given 
at 2 and 4 days after the initial intravenous injection of DEX 
to ensure that reactivation occurs. We have previously 
demonstrated that multiple injections of DEX enhance shed 
ding of virus (Jones et al., 2000). Calves were housed under 
Strict isolation containment and given antibiotics before and 
after BHV-1 infection to prevent secondary bacterial infec 
tion. 
0.072 Nasal Swabs, ocular Swabs, and serum samples 
were taken at the designated times. Nasal and ocular Swabs 
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were stored at -80 C. in 2 ml of tissue culture medium 
Supplemented with 10 ug of amphotericin B per ml (Fun 
gizone) and 45 ug of gentamicin per ml. Samples were 
thawed quickly in a 37 C. water bath, vortexed, and 
centrifuged (1,500xg for 10 min). All titrations were per 
formed with 10-fold serial dilution and plated in quadrupli 
Cate. 
0073 Virus was isolated from TG by mincing 0.5g of 
tissue, Suspending the tissue in 9 ml of Dulbecco's modified 
Eagle's medium (DMEM), and homogenizing the tissue 
with a tissue grinder (Polytron, Switzerland). One milliliter 
of fetal bovine Serum was added, and the homogenate was 
Subjected to three freeze-thaw cycles with a dry ice-ethanol 
bath. After the last cycle, the homogenate was centrifuged at 
2,000 rpm (Jouan CR412 centrifuge) for 30 min at 4°C. The 
Supernatant from the TG homogenate was Subsequently used 
to infect MDBK cells. The TG Supernatant (125 ul) was 
added to 500 ul of medium (1:5 dilutions), and then 1:5 
serial dilutions were made. One hundred microliters of each 
dilution was added in quadruplicate to a 96-well plate. One 
hundred microliters of MDBK cells (10 cells) was added to 
each well. After 4 days of incubation, cells were fixed and 
then stained with formaldehyde-bromophenol blue. Virus 
titers were measured with the 50% end point assay as 
described previously (Inman et al., 2001B). 
0074 C. Nucleic Acid Tissue Extraction 
0075 RNA and DNA extractions from MDBK cells or 
TG were performed as previously described (Jones et al., 
2000; Schang and Jones, 1997). 
0.076 D. Reverse Transcription of RNA to Obtain cDNA 
0077 Reverse transcription (RT) was performed essen 
tially as previously described (Jones et al., 2000). Briefly, 4 
lug of RNA was treated with DNase, and after inactivation, 
the RNA was reverse transcribed with random hexamers as 
primers. As a control for DNA contamination in the RNA 
samples, DNase-treated RNA was mixed with the RT reac 
tion mix lacking reverse transcriptase. Two microliters was 
used for PCR. 
0078 E. PCR 
0079 PCR was performed on the extracted DNA and 
synthesized cDNA with the indicated primer pairs p4(nucle 
otide nt) 873, 5'CGTGTATTTGCGACCCCCAGCCT3' 
(SEQ ID NO:1)) and p5 (nt 596, 5'GCCAGACCAAAC 
CCCCCGCA3' (SEQ ID NO:2)) (Inman et al., 2001B; 
Schang and Jones, 1997). Actin, L3B, and gC primers have 
been described previously (Hossain et al., 1995; Inman et 
al., 2001B; Jones et al., 2000; Schang and Jones, 1997). The 
gC forward primer is 5' AAAGCCCCGCCGAAGGAG 
(SEQ ID NO:3) (bp 550 of the BHV-1 gC gene). The gC 
reverse primer is 5'TACGAACAGCAGCACGGGC (SEQ 
ID NO:4) (bp 756 of BHV-1 gC gene). The forward bovine 
growth hormone (gH) primer is 5' GCTTTCGCCCT 
GCTCTGCC (SEQ ID NO:5) (bp 994 of the bovine growth 
hormone gene). The reverse gH primer is 5'TCCTGCCTC 
CCCACCCCTA (SEQ ID NO:6) (bp 1155 of the bovine 
growth hormone gene). After a hot start, each cycle con 
sisted of 95° C. for 1 min, 60° C. for 1 min, and 72 C. for 
2 min (30 cycles total). To ensure complete elongation of 
amplified products, the reaction was incubated at 72 C. for 
an additional 10 min. For some studies, the PCR products 
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were digested with EcoRI, electrophoresed on a 2% agarose 
gel, and the DNA was visualized by staining with ethidium 
bromide. 
0080 F. Direct Fluorescence Assay for the Detection of 
BHV-1 
0081 For the direct fluorescence assay (FA), a 24-well 
plate of MDBK cells was infected with clarified viral lysate. 
Twenty-four hours later, cell monolayers were fixed for 5 
min with ice-cold methanol-acetone (50:50) and then 
allowed to dry. A 1:50 dilution of direct conjugate (anti 
BHV-1-specific antibody-fluorescein isothiocyanate FITC 
conjugate; American Bioresearch, Milton, Tenn.) was 
added to the fixed cells and incubated at 37 C. for 30 min. 
The monolayers were washed twice with phosphate-buff 
ered Saline. The presence of virus was visualized with an 
FITC filter. 
0082) G. BHV-1-Specific Neutralizing Antibodies 
0083) The Veterinary Diagnostic Service, University of 
Nebraska, Lincoln, measured neutralizing antibody titers 
with the Cooper Strain as the Stock virus, using Standard 
materials and methods. 
0084. H. In Situ Hybridization 
0085) DNA probes specific for BHV-1 gC, ribonucleotide 
reductase, blCP0, and the LR gene were used. Labeling of 
the probes and hybridization Steps were performed as pre 
viously described (Winkler et al., 1999; Winkler et al., 
2000). After hybridization, slides were washed twice in 
4xSSC (1xSSC is 0.15 MNaCl plus 0.015M sodium citrate) 
for 5 min at room temperature, once in 2XSSC at 40 C., 
once in 0.5xSSC at 40° C., twice in 2XSSC at room 
temperature, twice in 0.5xSSC at room temperature, and 
once in buffer I (100 mM maleic acid, 150 mM NaCl pH 
7.5). The conjugate antibody Step and reaction development 
were also performed as previously described (Winkler et al., 
1999; Winkler et al., 2000). 
EXAMPLE 2 
Construction of a BHV-1 LR Mutant Virus 
0086) To determine whether BHV-1 LR gene products 
play a role in virus growth and/or latency, a BHV-1 LR 
mutant virus that contains Stop codons near the 5' terminus 
of the LR transcript was constructed and tested in cultured 
cells and calves. 
0087. The LR gene is transcribed antisense with respect 
to the immediate-early (IE) and early (E) gene transcript 
(IE/2.9 and E/2.6) that encodes b|CP0. The lytic start site for 
the LR RNA is at nt 724 (Ahmed et al., 2002; Hariharan et 
al., 1993), and the first in-frame ATG for LR open reading 
frame 2 (ORF2) is at nt 783 to 785, whereas the stop site for 
bICPO is at nt 956 (LR numbers) (Devi-Rao et al., 1994; 
Rock et al., 1987A; Rock et al., 1987B; Sawtell, 1997), 
which complicates construction of an LR mutant Virus. The 
cis-acting sequences that regulate poly(A) addition for the 
transcript that encodes blCP0 are also near Sequences that 
contain the LR gene TATA box. This prevented insertion of 
a reporter gene near the Start Site of LR gene expression or 
an extensive deletion of LR gene Sequences. Consequently, 
we inserted three Stop codons to prevent LR protein expres 
Sion in all three reading frames. This mutation was also 
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designed to allow for WT levels of blCPO expression. The 
entire promoter and coding region of the LR gene was 
cloned into the pBlueBachisA vector as described previ 
ously (Inman et al., 2001B). A total of 825 bases from the 
adjacent HindIII L fragment (Inman et al., 2001A) were 
cloned upstream of the LR promoter to ensure that efficient 
homologous recombination occurred. The LR sequences 
between the two SphI sites (nt 781 to 812) were replaced 
with the mutant oligonucleotide. The mutant oligonucleotide 
contains the first in-frame ATG of ORF2, a unique EcoRI 
restriction site to facilitate Screening, and three Stop codons 
that are in each reading frame. In transiently transfected 
cells, this LR mutant gene construct expresses the LRRNA, 
but the protein detected by a peptide antibody directed 
against the N terminus of LR ORF2 (P2) is not detected 
(Carter et al., 1989; Hariharan et al., 1993). 
0088 BHV-1 DNA was extracted from infected cells, and 
its integrity was examined by agarose gel electrophoresis. 
BHV-1 DNA is not very infectious when transfected into 
cultured bovine epithelial cells. Efficient plaque formation 
was not observed at 14 days posttransfection, a time when 
cells were lifting off the plates. When BHV-1 DNA and 
plasmids encoding b|CPO (Inman et al., 2001C) or HSV-1 
ICPO were cotransfected into bovine cells, efficient plaque 
formation was consistently observed 48 h after transfection. 
A plasmid expressing HSV-1 ICPO was used for these 
studies because bCPO sequences overlapped the LR mutant 
region, and thus we were concerned this might reduce the 
efficiency of homologous recombination. 
0089. The viral genome was cotransfected into bovine 
epithelial cells with HSV-1 ICPO and the plasmid containing 
the mutant oligonucleotide (pBlueL/mLAT). Plaques were 
isolated and Screened for insertion of the mutant oligonucle 
otide sequence by PCR using the p4 and p5 primers. The 
amplified products were then digested with EcoRI. If 
homologous recombination between the LR mutant plasmid 
and the viral genome occurred, two bands (105 and 193 bp) 
would be observed following digestion with EcoRI. WT 
virus yielded a single band (298 bp) as expected. After the 
potential LR mutants were Subjected to three rounds of 
plaque purification, the same banding pattern was observed, 
demonstrating that the mutant virus from a plaque was not 
contaminated with WT virus and was stable. Several plaques 
containing the mutant were Selected and plaque purified two 
more times to ensure they were not contaminated with WT 
WUS. 
0090. To ensure that a resulting phenotype was not due to 
Secondary Site mutations, a rescued virus was constructed 
(LR rescued virus). The LR mutant viral genome was 
cotransfected with the WT LR gene cloned into pBlueBa 
cHisA(pblueL/LAT) and a plasmid encoding HSV-1 ICPO 
into bovine cells. The p4 and p5 primers were used to 
identify amplified products that were not digested by EcoRI, 
which was indicative of the LR WT gene. Viral sequences 
encompassing the manipulated regions of the LR gene in the 
LR mutant and LR rescued virus were Sequenced and 
contained the expected Sequences. 
EXAMPLE 3 
Analysis of the BHV-1 LR Mutant Virus in MDBK 
Cells 
0091) Infection of MDBK cells with BHV-1 Cooper 
strain produces visible cytopathic effects by 7 to 10 hp.i. 
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followed by efficient plaque formation. IE gene expression 
can be detected within 1 to 2 hp.i. Although not statistically 
Significant, growth curves Suggested that the mutant released 
virus slightly faster from MDBK cells early in infection at 
an MOI of 1. However, the end point titers were consistently 
the same. At an MOI of 5, there were no differences in the 
titers of cell-associated and released virus. It was consis 
tently observed that resting cells or cells that were too 
confluent did not yield as much virus as actively growing 
cells. However, the LR mutant and WT virus had similar 
growth properties in MDBK cells. LR mutant, LR rescued, 
and WT viruses also had similar growth properties in rabbit 
epidermal (CCL-68; ATCC), rabbit lung (CCL-193; ATCC), 
rabbit skin fibroblasts (CRL-1414; ATCC), and bovine epi 
dermal cells. 
0092. The LR RNA is antisense to the IE and E transcript 
that is translated into b|CP0(Jones 1998), suggesting blCP0 
expression could be altered by the mutation within the LR 
gene. Since bCP0 is essential for productive viral replica 
tion (Fraefel et al., 1994, Inman et al., 2001C; Koppel et al., 
1996), expression of blCP0 in the WT, LR rescued, and LR 
mutant viruses following infection of MDBK cells were 
compared. These Studies demonstrated that expression of 
bICPO in MDBK cells infected with the LR mutant was at 
least as high as in those infected with the WT or the LR 
rescued virus. 
EXAMPLE 4 
Construction of CJLAT 
0093. The plasmid p1658 contains two HSV-1 DNA 
restriction fragments. One restriction fragment (HpaI 
EcoRV) corresponds to the region from 1800 to 161 nucle 
otides upstream of the LAT start site (LAT nucleotides 
-1800 to -161). The other restriction fragment (HpaI-Mlul) 
corresponds to LAT nucleotides 1667 to 2850. A unique PacI 
restriction Site was cloned between these restriction frag 
ments (i.e., between LAT nucleotides -161 and +1667). PacI 
linkers were added to the complete BHV-1 LR gene DNA, 
which was then cloned into the above unique PacI restriction 
site of p1658. The LR gene was a 1.9-kb HindIII-Sall 
fragment derived from the HindIIID fragment of BHV-1 
strain Cooper (BHV-1 nucleotides 1 to 1941) that contains 
the LR promoter and the known coding sequences (Kutish et 
al., 1990). The resulting plasmid, CJLATP1658, was 
cotransfected with infectious dLAT2903 genomic DNA into 
RS cells as we previously described for construction o other 
HSV-1 mutants (Pering et al., 1994; Perng et al., 1996). After 
homologous recombination between the HSV-1 DNA flank 
ing the BHV-LR DNA in the plasmid and the genomic DNA 
flanking the LAT deletion in dLAT2903, the cotransfection 
mix was plated on RS cells, and Viral plaques were isolated. 
Individual plaques were analyzed by restriction digestion 
and Southern analysis. In the final chimeric virus, CJLAT, 
the core LAT promoter and the region of the LAT gene 
corresponding to the first 1.7-kb of the primary LAT tran 
script of HSV-1 McKrae has been replaced by the BHV-1 
LAT gene. CJLAT was triple plaque purified and its genomic 
Structure was confirmed by additional restriction digestion 
Southern analysis. 
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EXAMPLE 5 
Growth of LR Mutant Virus in TG of Acutely 
Infected Calves 
0094 BHV-1 LR mutant virus containing stop codons 
near the 5' terminus of the LR transcript (LR mutant) where 
constructed, as previously described (Inman et al., 2001B). 
The LR mutant grew to similar titers relative to wt or 
LR-rescued virus in the nasal cavity of calves and cultured 
bovine cells. However, the LR mutant shed approximately 4 
logs less infectious virus from eyes of acutely infected 
calves compared to wt or LR-rescued virus, Suggesting the 
LR gene plays a role in acute virus growth in certain bovine 
tissue. 
0.095 Presence of infectious virus. To test whether calves 
infected with the LR mutant contained different amounts of 
infectious virus in TG compared to calves infected with wt 
BHV-1, calves were infected with the respective viruses, TG 
were harvested at different times after infection, and infec 
tious virus was measured in TG homogenates. Levels of 
infectious virus in TG homogenates were measured by 
incubating the Supernatants with MDBK cells. Cultures that 
produced cytopathic effects were also Subjected to FA with 
BHV-specific antisera as an independent verification that 
cytopathic effects were due to virus infection and not non 
Specific toxic effects of the TG homogenates. At 2 and 4 dpi, 
calves infected with the LR mutant contained 10- to 100 
fold less virus in TG homogenates compared to calves 
infected with wt virus (FIG. 1). Infectious virus was not 
detected in TG of calves infected with the LR mutant on 6 
dpi. FA-positive Samples were detected at 6 dpi in LR 
mutant-infected calves and 10 dpi in calves infected with the 
wt (data not shown), but the amount of virus was too low for 
titration. 
0096 Presence of LR mutant genome. To verify that the 
LR mutant genome was present in TG of calves infected 
with the LR mutant, PCR analysis was performed. DNA was 
prepared from calves infected for 6 or 10 dpi and Screened 
for the presence of the mutant by PCR with the p4 and p5 
primerS. Amplified products were then digested with EcoRI. 
Calves infected with the LR mutant contained two bands 
(105 and 193 bp) that were detected following digestion 
with EcoRI. The presence of wt virus yields a single band of 
298 bp, while LR mutant virus yields two bands migrating 
at 105 and 193 bp. The LR mutant plasmid and a plasmid 
with the wt LR gene were used as positive controls to show 
the positions of the expected products. PCR of representa 
tive samples from calves infected for 6 or 10 days demon 
strates that only the inoculated virus was detected in the TG. 
In Summary, this Study demonstrated that, during acute 
infection, lower levels of infectious virus were present in TG 
of calves infected with the LR mutant. 
0097 Analysis of BHV-1 DNA in calves infected with 
the LR mutant or wt DNA. In situ hybridization was 
performed with probes that specifically bind to four viral 
genes (Winkler et al., 1999; Winkler et al., 2000). Thin 
sections were prepared from TG of calves infected with the 
LR mutant or wt virus at 10 (end of acute infection or 
establishment of latency) or 60 (latency) dpi. In situ hybrid 
ization was performed as described in Example 1. In Situ 
positive neurons in TG were consistently detected in thin 
sections prepared from calves infected with wt virus at 10 
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and 60 dpi. We estimated that less than 5% of the total 
neurons contained viral DNA, as judged by in situ hybrid 
ization. In contrast, DNA-positive neurons were not detected 
by in situ hybridization with TG thin sections prepared from 
calves infected with the LR mutant for 10 or 60 days after 
infection, This Study Suggested that neurons with high 
copies of viral DNA were not present in TG of calves 
infected with the LR mutant. 
0098. To further compare the levels of viral DNA in TG 
of calves infected with the wt virus or the LR mutant, a 
semiquantitative PCR was performed as described in 
Example 1. PCR primers were used to detect BHV-1 gC 
DNA and bovine growth hormone (gH). PCR products were 
electrophoresed on 2% agarose gels, and the DNA was 
stained with ethidium bromide. DNA prepared from: TG of 
a mock-infected calf, MDBK cells infected with BHV-1 
(MOI=1) for 24 h; and from BHV-1 virions (purified) were 
included as controls. For each DNA sample, 1 lug of DNA 
was used for PCR. 20 ng of purified viral DNA was used for 
PCR. 
0099 We focused on samples prepared from latently 
infected calves 60 days after infection (60 dpi) or during the 
early stages of reactivation (24 and 48 h after Single intra 
venous injection with DEX). As expected, wt viral DNA was 
readily detected in TG of latently infected calves and at 24 
or 48 h after DEX treatment. In contrast, TG prepared from 
calves latently infected with the LR mutant did not contain 
detectable levels of viral DNA. At 24 h after DEX treatment, 
neither of two calves latently infected with the LR mutant 
contained detectable levels of viral DNA. At 48 h after DEX 
treatment, one of three calves latently infected with the LR 
mutant contained detectable levels of viral DNA. Under the 
conditions of this PCR assay, we were able to detect 
approximately 200 to 400 copies of viral DNA per ug of total 
DNA. In Summary, two independent assays (in Situ hybrid 
ization and PCR) demonstrate that calves latently infected 
with the LR mutant contained less viral DNA in TG. 
EXAMPLE 6 
LR-RNA Expression in Calves Latently Infected 
with the LR Mutant 
0100. In theory, the LR mutant should express LR-RNA, 
but not proteins because of the three stop codons (Inman et 
al., 2001B). RNA was extracted from TG of infected calves 
or MDBK cells as described in Example 1. cDNA was 
generated with random primers and PCR was performed 
with Specific primerS. Primers that amplify a Segment of the 
B-actin transcript flank an intron, which allows for detection 
of contaminating DNA as previously described (Inman et al., 
2001B). L3B primers were used to detect the LR transcript. 
Primers that amplify gC RNA were used to verify that calves 
were in the latent phase of infection. When reverse tran 
scriptase was omitted during cDNA synthesis, no PCR 
product was detected. In productively infected bovine cells, 
the LR mutant expressed abundant levels of LR-RNA. 
LR-RNA expression was examined in TG of calves infected 
with the LR mutant at 60 dpi (latency). RT-PCR was 
performed with primers that specifically amplify LR-RNA 
(L3B) as described previously (Ciacci-Zanella et al., 1999; 
Hossain et al., 1995; Jones et al., 2000). LR-RNA was 
detected in two of two calves infected with the LR mutant 
and, as expected, in two of two calves infected with the wt 
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at 60 dpi. gC RNA was not detected by RT-PCR in latently 
infected calves, demonstrating that high levels of productive 
infection were not occurring in TG during latency (60 days 
after infection). 
EXAMPLE 7 
Effect of DEX on Reactivation of the LR Mutant 
0101 Treatment of latently infected rabbits (Rock et al., 
1992) or calves (Jones et al., 2000; Sheffy and Davies, 1972) 
with DEX consistently reactivates BHV-1 from latency. 
Consequently, Virus Shedding occurs in ocular or nasal 
cavities, and virus-specific antibodies increase. A prelimi 
nary Study was performed with two calves latently infected 
with the LR mutant, two calves infected with wt virus, and 
two calves infected with the LR-rescued virus. Following a 
single intravenous injection of DEX (100 mg), we detected 
reactivation in calves latently infected with wt or the LR 
rescued virus, but not the two calves infected with the LR 
mutant, Suggesting the LR mutant was not capable of 
reactivating. To confirm this result, a larger Study was 
performed with an initial intravenous injection of DEX (100 
mg) followed by two intramuscular injections of DEX (25 
mg) to ensure that reactivation occurred efficiently. Our 
previous Studies demonstrated that multiple injections of 
DEX allowed efficient reactivation of a temperature-sensi 
tive mutant of BHV-1, which is used as a modified live 
vaccine and is severely attenuated (Jones et al., 2000). 
0102 Neutralizing antibody titers were measured after 
DEX treatment to determine if reactivation occurred. Serum 
was collected from calves at the indicated times and Stored 
at -20° C. until tested. Standard testing was performed with 
constant amounts of virus (Cooper strain) and twofold Serial 
dilutions of the serum. The Veterinary Diagnostic Services, 
University of Nebraska, Lincoln, performed the assay. AS 
expected, a dramatic increase in Virus-specific antibodies 
was detected in animals infected with wt or LR-rescued 
virus after DEX-induced reactivation (FIG. 3), indicating 
that virus replication and Shedding occurred. A five- to 
Sixfold increase in antibody titers was detected, which is 
consistent with reactivation from latency. In contrast, an 
increase in Virus-specific antibodies was not observed when 
calves latently infected with the LR mutant were treated 
with DEX. 
0103) To confirm the neutralizing antibody results, ocular 
and nasal Swabs were collected from each calf at the 
designated times after treatment with DEX. Infectious virus 
in Swabs was detected by inoculating MDBK cells with a 
1:20 dilution of the Swab medium Solution. FA was used to 
confirm the presence of infectious BHV-1 in cultures con 
taining cytopathic effects. AS expected, during latency, wit, 
rescued, or LR mutant virus was not detected in Swabs on the 
day of DEX treatment (day 0). At 4 and 7 days after DEX 
treatment, infectious virus was detected in Swabs obtained 
from Six of Seven and Seven of Seven calves latently infected 
with wt virus (FIG. 4). At 4 and 7 days after DEX treatment, 
infectious virus was detected in four of four calves infected 
with the rescued virus. At these time points, infectious virus 
was detected in nasal and ocular Swabs of calves Shedding 
wt and LR-rescued virus. To simplify the data, the ocular 
and nasal results were combined. In Sharp contrast, infec 
tious virus was not detected in Seven of Seven calves latently 
infected with the LR mutant at any time point tested. 
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Infectious virus was not detected in nasal or ocular Swabs of 
any calf after 10 days postreactivation. These Studies dem 
onstrated that the LR mutant did not reactivate from latency 
following multiple injections of DEX. 
DEPOSIT INFORMATION 
0104. The live, attenuated BHV-1 strain has been depos 
ited with the American Type Culture Collection (ATCC), 
10801 University Boulevard, Manassas, Va. 20110-2209, 
USA, on , in accordance with the Budapest Treaty 
and has been accorded Accession Number 
0105 From the foregoing it will be seen that this inven 
tion is one well adapted to attain all ends and objectives 
herein-above Set forth, together with the other advantages 
which are obvious and which are inherent to the invention. 
0106 Since many possible embodiments may be made of 
the invention without departing from the Scope thereof, is to 
be understood that all matters herein set forth or shown in 
the accompanying drawings are to be interpreted as illus 
trative, and not in a limiting Sense. 
0107 While specific embodiments have been shown and 
discussed, various modifications may of course be made, 
and the invention is not limited to the Specific forms or 
arrangement of parts and Steps described herein, except 
insofar as Such limitations are included in the following 
claims. Further, it will be understood that certain features 
and Sub-combinations are of utility and may be employed 
without reference to other features and Sub-combinations. 
This is contemplated by and is within the scope of the 
claims. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 8 
<21 Oc 
<211 
<212> 
<213> 
<22O > 
<223> 
SEQ ID NO 1 
LENGTH 23 
TYPE DNA 
ORGANISM: Artificial 
FEATURE 
OTHER INFORMATION: p. 4 primer 
<400 SEQUENCE: 1 
cgtgt atttg cq accoccag cott 
SEQ ID NO 2 
LENGTH 2.0 
TYPE DNA 
ORGANISM: Artificial 
FEATURE 
OTHER INFORMATION: p5 primer 
<400 SEQUENCE: 2 
gccagaccala accoccc.gca 
SEQ ID NO 3 
LENGTH 18 
TYPE DNA 
ORGANISM: Artificial 
FEATURE 
OTHER INFORMATION: forward gC primer 
<400 SEQUENCE: 3 
aaa.gc.ccc.gc cqaaggag 
SEQ ID NO 4 
LENGTH 19 
TYPE DNA 
ORGANISM: Artificial 
FEATURE 
OTHER INFORMATION: reverse gC primer 
<400 SEQUENCE: 4 
tacgaac agc agcacgggc 
<210 SEQ ID NO 5 
&2 11s LENGTH 19 
&212> TYPE DNA 
<213> ORGANISM: Artificial 
13 
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-continued 
&220s FEATURE 
<223> OTHER INFORMATION: forward gH primer 
<400 SEQUENCE: 5 
gcttitc.gc.cc td citctg.cc 
SEQ ID NO 6 
LENGTH 19 
TYPE DNA 
ORGANISM: Artificial 
FEATURE: 
OTHER INFORMATION: reverse gH primer 
<400 SEQUENCE: 6 
toctg.cctcc ccaccocta 
SEQ ID NO 7 
LENGTH 37 
TYPE DNA 
ORGANISM: Bovine herpesvirus 1 
<400 SEQUENCE: 7 
gcatgcgcga cct gggcc at aaaag.ccc.cg cqcatgc 
SEQ ID NO 8 
LENGTH 2.8 
TYPE DNA 
ORGANISM: Artificial 
FEATURE: 
OTHER INFORMATION: mutant oligonucleotide 
<400 SEQUENCE: 8 
gcatgcagaa ttctagittag ttago atg 
What is claimed and desired to be secured by Letters Patent 
is as follows: 
1. A vaccine composition against a viral or bacterial 
pathogen, comprising a viral vector, wherein Said viral 
vector is a mutant recombinant BHV-1 Strain comprising: 
a. a mutation in the latency-related (LR) gene, whereby no 
detectable reactivation from latency occurs, and 
b. an expressable recombinant nucleic acid encoding an 
antigen from Said viral or bacterial pathogen, wherein 
expression of Said antigen induces immunological 
response against Said viral or bacterial pathogen. 
2. The vaccine composition of claim 1, wherein Said viral 
vector comprises modified BHV-1 strain on deposit with the 
American Type Culture Collection as Accession No. 
3. The vaccine composition of claim 1, wherein Said 
mutation in the LR gene is accomplished by chemical 
Synthesis or artificial manipulation of isolated Segments of 
nucleic acid. 
4. The vaccine composition of claim 1, wherein Said 
mutation in the LR gene is spontaneous or a Selected, 
naturally occurring mutation. 
5. The vaccine composition of claim 1, wherein the live, 
attenuated BHV-1 strain comprises a modified BHV-1 strain 
other than the BHV-1 strain on deposit with the American 
Type Culture Collection as Accession No. VR-864. 
19 
19 
37 
28 
6. The vaccine composition of claim 1, wherein Said 
mutated LR gene comprises the nucleotide Sequence of SEQ 
ID NO:8. 
7. The vaccine of claim 1, wherein said expressable 
recombinant nucleic acid is inserted in Said mutated LR gene 
locus, whereby expression of the recombinant nucleic acid 
is driven by the LR promoter. 
8. The vaccine of claim 1, wherein said expressable 
recombinant nucleic acid is inserted in a glycoprotein locus 
of the viral vector, whereby expression of the recombinant 
nucleic acid is driven by a heterologous promoter. 
9. The vaccine composition of claim 1, wherein said 
vaccine is adapted for administration by a mode Selected 
from the group consisting of intranasal instillation, intra 
muscular, ocular, intraperitoneal, and Subcutaneous. 
10. The vaccine composition of claim 1, wherein said 
Viral or bacterial pathogen is Selected from the group con 
Sisting of bovine herpesvirus 1, bovine viral diarrhea virus, 
bovine respiratory virus, bovine corona virus, Pasteurella 
haemolytica, Pasteurella multocida, and Haemophilus SOm 
S. 
11. A method of modulating the immune response to a 
Viral or bacterial infection, which comprises administering a 
vaccine composition according to claim 1. 
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12. A method of vaccinating a mammal in need thereof 
against a viral or bacterial pathogen, which comprises 
administering to Said mammal a vaccine composition 
according to claim 1. 
13. The method of claim 12, wherein said mammal is an 
ungulate. 
14. The method of claim 13, wherein said ungulate is 
Selected from the group consisting of bovines, buffalo, 
sheep, and deer. 
15. The method of claim 12, wherein said viral or bacte 
rial pathogen is Selected from the group consisting of bovine 
herpesvirus 1, bovine viral diarrhea virus, bovine respiratory 
virus, bovine corona virus, Pasteurella haemolytica, Pas 
teurella multocida, and Haemophilus SOmnus. 
16. A recombinant viral vector comprising SEQ ID NO:8 
and a recombinant nucleic acid fragment capable of encod 
ing an antigen from a viral or bacterial pathogen. 
17. The recombinant viral vector of claim 16, wherein 
Said viral or bacterial pathogen is Selected from the group 
consisting of bovine herpesvirus 1, bovine viral diarrhea 
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Virus, bovine respiratory virus, bovine corona virus, Pas 
teurella haemolytica, Pasteurella multocida, and Haemo 
philus SOmnus. 
18. A method for effecting the treatment of a viral or 
bacterial infection, which comprises administering to a 
mammal in need of Said treatment, an effective amount of 
the vaccine of claim 1. 
19. The method of claim 18, wherein said mammal is an 
ungulate. 
20. The method of claim 19, wherein said ungulate is 
Selected from the group consisting of bovines, buffalo, 
sheep, and deer. 
21. The method of claim 18, wherein said viral or bacte 
rial pathogen is Selected from the group consisting of bovine 
herpesvirus 1, bovine viral diarrhea virus, bovine respiratory 
virus, bovine corona virus, Pasteurella haemolytica, Pas 
teurella multocida, and Haemophilus SOmnus 
